Which Institutions Own Shares In Veracyte Inc. (VCYT)?

280 institutions hold shares in Veracyte Inc. (VCYT), with 443.88k shares held by insiders accounting for 0.77% while institutional investors hold 108.47% of the company’s shares. The shares outstanding are 66.44M, and float is at 57.64M with Short Float at 6.92%. Institutions hold 107.64% of the Float.

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is ARK Investment Management, LLC with over 7.02 million shares valued at $228.04 million. The investor’s holdings represent 12.12% of the VCYT Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.28 million shares valued at $258.45 million to account for 9.12% of the shares outstanding. The other top investors are William Blair Investment Management, LLC which holds 5.21 million shares representing 9.00% and valued at over $254.88 million, while Wellington Management Company, LLP holds 7.24% of the shares totaling 4.19 million with a market value of $136.27 million.

Veracyte Inc. (NASDAQ: VCYT) is 28.91% higher on its value in year-to-date trading and has touched a low of $13.90 and a high of $86.03 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VCYT stock was last observed hovering at around $72.96 in the last trading session, with the day’s loss setting it -9.87% off its average median price target of $86.50 for the next 12 months. It is also 33.59% off the consensus price target high of $95.00 offered by 8 analysts, but current levels are 2.94% higher than the price target low of $65.00 for the same period.

Currently trading at $63.09, the stock is -6.96% and 7.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing -13.53% at the moment leaves the stock 57.31% off its SMA200. VCYT registered 149.96% gain for a year compared to 6-month gain of 78.98%. The firm has a 50-day simple moving average (SMA 50) of $61.15 and a 200-day simple moving average (SMA200) of $46.09.

The stock witnessed a 16.90% loss in the last 1 month and extending the period to 3 months gives it a 31.44%, and is -16.69% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.19% over the week and 8.96% over the month.

Veracyte Inc. (VCYT) has around 354 employees, a market worth around $3.94B and $117.50M in sales. Profit margin for the company is -26.30%. Distance from 52-week low is 353.88% and -26.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-6.30%).

Veracyte Inc. (VCYT) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Veracyte Inc. (VCYT) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.

Veracyte Inc. is expected to release its quarterly report on 05/04/2021 and quarterly earnings per share for the current quarter are estimated at -$0.12 with sales reaching $32.03M over the same period.The EPS is expected to grow by 56.00% this year, but quarterly earnings will post 65.10% year-over-year. Quarterly sales are estimated to grow 2.90% in year-over-year returns.

Veracyte Inc. (VCYT) Insider Activity

A total of 79 insider transactions have happened at Veracyte Inc. (VCYT) in the last six months, with sales accounting for 46 and purchases happening 33 times. The most recent transaction is an insider sale by Anderson Bonnie H, the company’s Chairman and CEO. SEC filings show that Anderson Bonnie H sold 18,541 shares of the company’s common stock on Jan 13 at a price of $51.05 per share for a total of $0.95 million. Following the sale, the insider now owns 0.2 million shares.

Veracyte Inc. disclosed in a document filed with the SEC on Jan 12 that Anderson Bonnie H (Chairman and CEO) sold a total of 20,354 shares of the company’s common stock. The trade occurred on Jan 12 and was made at $50.20 per share for $1.02 million. Following the transaction, the insider now directly holds 0.2 million shares of the VCYT stock.

Still, SEC filings show that on Jan 11, Anderson Bonnie H (Chairman and CEO) disposed off 71,105 shares at an average price of $50.62 for $3.6 million. The insider now directly holds 203,756 shares of Veracyte Inc. (VCYT).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Veracyte Inc. (VCYT): Who are the competitors?

The company’s main competitors (and peers) include Exact Sciences Corporation (EXAS) that is 42.35% higher over the past 12 months. Myriad Genetics Inc. (MYGN) is 52.32% up on the 1-year trading charts. Short interest in the company’s stock has fallen -5.76% from the last report on Dec 30, 2020 to stand at a total of 4.22 million short shares sold with a short interest ratio of 6.01.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free